血管免疫母细胞性T细胞淋巴瘤:不止是滤泡辅助性T细胞疾病
本文解读J Pathol近期研究:用显微切割分离AITL中PD1+肿瘤细胞与CD20+B细胞,发现TET2突变在显微切割的PD1+肿瘤细胞中达12/13,而全组织仅6/13,且6/9例可评估的微环境CD20+B细胞也携带TET2突变。提示TET2突变是多数AITL的早期事件,驱动性分子异常不限于T细胞肿瘤成分。
要点
- TET2突变在显微切割的PD1+ AITL肿瘤细胞中检出率高于全组织检测。
- AITL微环境中的CD20+B细胞也可携带TET2突变。
- TET2突变可能是多数AITL的早期事件,异常不限于T细胞。
核心结论
- TET2突变是多数AITL病例的早期事件,且驱动性分子异常不限于T细胞肿瘤细胞。
研究设计与样本
- 原文为对近期发表于Journal of Pathology研究的解读,采用显微切割分离PD1+ AITL肿瘤细胞与CD20+B细胞进行突变分析。
主要发现
- 全组织检测中13例AITL仅6例检出TET2突变,而显微切割的PD1+ AITL肿瘤细胞13例中12例携带该突变。
- 在9例可评估病例中,6例AITL微环境的CD20+B细胞检出TET2突变。
- AITL由TFH表型的肿瘤细胞与含B细胞等多种反应性细胞的广泛微环境两部分组成。
- 复发性TET2突变在50-80%的AITL中报道,可能发生于造血祖细胞。
临床怎么用
- AITL的分子评估不应仅针对T细胞肿瘤成分,微环境B细胞也可能携带TET2突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most frequent entities of peripheral T-cell lymphoma. An AITL has two components: the AITL tumour cells, which have a T follicular helper (TFH) cell phenotype, and a surrounding and extensive tumour microenvironment that is populated with various reactive cell types, including B cells. Recurrent TET2 mutations have been described in 50-80% of AITLs, possibly occurring in a haematopoietic progenitor cell. An article published recently in the Journal of Pathology describes the use of microdissection to isolate PD1+ AITL tumour cells and CD20+ B cells from the AITL microenvironment, and to show that TET2 mutations are actually more frequent in these diseases than previously thought. Whereas TET2 mutations were detected in only six of 13 AITLs, 12 of 13 samples of microdissected PD1+ AITL tumour cells possessed this mutation. Moreover, TET2 mutations were detected in CD20+ B cells from the AITL microenvironment in six of nine informative cases. These results confirm that TET2 mutation is an early event in the majority of AITL cases, and that the driving molecular anomalies are not restricted to the T lineage tumour cells. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
- Lemonnier F, Mak TW. Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol. 2017. PMID: 28543514. doi:10.1002/path.4920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。